Heartflow FFRCT Analysis Shows Improved Outcomes and Cost Savings in NHS Study of 90,000 Patients

Reuters
2025/12/11
Heartflow FFRCT Analysis Shows Improved Outcomes and Cost Savings in NHS Study of 90,000 Patients

Heartflow Inc. announced new analyses from the FISH&CHIPS study, a real-world, multicenter, retrospective study involving over 90,000 patients conducted by the National Health Service in England. The results, which were presented at the European Society of Cardiology's European Association of Cardiovascular Imaging conference in Vienna, indicate that Heartflow FFRCT Analysis derived from coronary computed tomography angiography improves diagnostic decision-making, predicts future cardiovascular events, and delivers system-wide cost savings. Additional findings from a subset of the study were previously presented at the American Heart Association Scientific Sessions 2025, validating Heartflow Plaque Analysis as a predictor of future heart attacks or cardiovascular death.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartflow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600533-en) on December 11, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10